SwitzerReport

Independent. Trusted. Proven.

Reports

Browse current and previous editions of Switzer Report

Monday Edition, 5 February 2024
Paul Rickard

Portfolios show solid gains as market hits a record high

Paul Rickard · February 5, 2024

Led by Wall Street, the Aussie share market hit a record high at the end of January. Our Switzer model portfolios followed suit and recorded solid gains for the month, outperforming the benchmark index. In this article, I look at how they’ve performed so far this year.

Investing Premium
James Dunn

Two cheap mining services opportunities

James Dunn · February 5, 2024

Here are two mining services companies I think have good potential to rise from here – one larger business, with a lot of work outside Australia, and the other (one-tenth the size) mainly confined to its home state of Western Australia.

Investing Premium
Switzer on Saturday, 3 February 2024
Thursday Edition, 1 February 2024
Paul Rickard

Questions of the Week

Paul Rickard · February 1, 2024

Will ANZ succeed in its purchase of Suncorp Bank, and what is the outlook for insurance companies such as Suncorp? With Evolution Mining, should I cut now and bail? What is your exit price for RIO? Are there any good graphite stocks on the ASX?

Q&A Premium
Monday Edition, 29 January 2024
Peter Switzer

Why I like lithium

Peter Switzer · January 29, 2024

I’m going long lithium, backing billionaires like Elon Musk and Gina Rinehart, even though I know I might have to wait a long time to get the big pay-off.

Investing Premium
Paul Rickard

Why I think term deposits are still attractive

Paul Rickard · January 29, 2024

I’m a great believer in term deposits in an investor’s portfolios (if the rate and term is right) because term deposits are one of the few investments where retail investors get better rates than wholesale investors. This is for two reasons, which I explain here today.

Investing Premium
Maureen Jordan

HOT stock: Resmed (RMD)

Maureen Jordan · January 29, 2024

For our “HOT” stock today, Raymond Chan, Head of Asian Desk at Morgans explains was he sees Resmed (RMD) as an ADD to an investor’s portfolio.

Investing Premium
1 71 72 73 74 75 109

You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.